Ad5-nCov

BIOLOGICAL2 trials

Sponsors

Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China, Fundación Huésped

Conditions

COVID-19COVID-19 Vaccine

Phase 1

A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults

CompletedNCT04552366

Institute of Biotechnology, Academy of Military Medical Sciences, PLA of ChinaCOVID-19

Start: 2020-09-29End: 2021-04-30Updated: 2023-05-24

Phase 2

Phase IIB Study of Recombinant Novel Coronavirus Vaccine

CompletedNCT05293223

Fundación HuéspedCOVID-19 Vaccine

Start: 2021-10-01End: 2023-12-15Updated: 2025-06-25

Related Papers

Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

2023-11-1548 citations

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.

2021-07-26219 citations